For 60 years, clinical trial data has moved on a one-way delay: sites collect it, sponsors analyze it, and only then does it reach the FDA, sometimes years after a safety signal first appeared. On April 28, 2026, the FDA (Food & Drug Administration) announced two major steps toward advancing its initiative on FDA real-time clinical trials (RTCT), improving that timeline.
The agency unveiled the successful initiation of two proof-of-concept RTCTs and released a Request for Information (RFI) on a broader pilot program set to launch this summer. Together, these moves mark one of the most concrete signals yet that real-time, AI-enabled clinical trial monitoring is moving from concept to practice, and they raise the bar for what sponsors, CROs, and technology partners need to be ready to deliver.
Two Proofs-of-Concept, One Bigger Goal
The FDA’s proof-of-concept trials are already running. AstraZeneca’s Phase 2 TRAVERSE trial*, in treatment-naïve mantle cell lymphoma, is enrolling at MD Anderson and Penn. Amgen’s Phase 1b STREAM-SCLC trial, in limited-stage small cell lung carcinoma, is finalizing site selection. For both, the FDA worked directly with the sponsor to define which signals and endpoints would be reported in real time, and the agency has already received and validated live signals from the AstraZeneca trial through its data partner, Paradigm Health.
FDA Commissioner Marty Makary framed the stakes plainly: a years-long lag time between data collection and regulatory visibility can delay decisions that matter to patients waiting on new treatments. Chief AI Officer Jeremy Walsh added that the agency wanted to prove real-time trials were achievable, not just theoretical, and that proof now exists.
Building on that foundation, the FDA’s RFI asks for industry input on pilot program design, eligibility, and success metrics, including how AI-enabled platforms should factor into the agency’s review process. The original May 29 comment deadline has since been extended to June 29, 2026, giving sponsors more time to weigh in before the FDA finalizes selection criteria in July and completes pilot selections in August.
From Phased Trials to Continuous Development
The proof-of-concept trials are a means to a larger end. Drug development today moves through discrete, sequential phases, each run under its own protocol, typically with a pause between when one phase ends and the next begins. The FDA’s stated goal is to use real-time visibility into safety and efficacy signals to shrink or eliminate that hiatus, working toward continuous trials that span the full arc of development.
That vision depends on infrastructure that doesn’t yet exist at scale across the industry: interoperable data pipelines, automated signal detection, and standardized ways to get trial data from source systems to regulators without the manual hand-offs that introduce delays today.
Saama’s Approach to Real-Time, AI-Driven Trials
This is the problem Saama has been building toward for years, and the FDA’s announcement validates the direction the industry is moving in. We’ve spent the past decade applying AI in clinical development with one goal in mind: closing the gap between when a signal appears in trial data and when the people who need to see it actually do. That focus has shaped our approach in a few consistent ways:
- Human oversight built in at every step, so speed never comes at the expense of accountability
- Continuous, automated data flows, rather than periodic, manual reporting cycles
- A decade of AI investment in life sciences, focused specifically on closing the time between data and decisions
Real-time clinical trials demand exactly this kind of automated, continuously updated data foundation.
What This Means for Sponsors and CROs
The FDA’s RFI is explicit that it wants industry input before locking in the rules of the pilot, which means the comment period through June 29 is a genuine opportunity to shape how eligibility, data standards, and success metrics get defined. A few open questions are worth tracking as the pilot takes shape:
- Eligibility: which sponsors, trial types, or technologies will qualify for the broader pilot
- Blinded trials: how real-time review fits alongside blinding requirements
- Data standards: what quality and privacy requirements will apply to continuous data exchange
Sponsors running early-phase oncology or other high-uncertainty programs have the clearest incentive to engage now, both with the FDA directly and with technology partners who can help them assess readiness. The direction is no longer in doubt: as the FDA moves from proof-of-concept to pilot, the sponsors best positioned to participate will be the ones who’ve already invested in the AI-driven data infrastructure this model assumes.
At Saama, we see this as the natural next chapter of work we’ve already been doing: building the connective tissue between trial data and the people who need it, faster, with trust and oversight built in from the start.
Want to know how real-time, AI-driven data infrastructure could prepare your trials for what’s next? Connect with our team to learn more about Saama’s approach to clinical AI.
AstraZeneca’s Phase 2 TRAVERSE trial: https://www.astrazenecaclinicaltrials.com/study/D822GC00001
FAQs
Q1. Why is the FDA launching a real-time clinical trial pilot?
A. The FDA wants to close the gap between when a safety signal or endpoint appears in trial data and when the agency actually sees it. Under the current model, that lag can stretch to years, delaying regulatory decisions and slowing down drug development timelines. The pilot builds on two successful proof-of-concept trials to test whether real-time data sharing can work at a broader scale, with the longer-term goal of enabling continuous trials across all phases of development.
Q2. What does FDA stand for in clinical trials?
A. FDA stands for the U.S. Food and Drug Administration, the federal agency responsible for protecting public health by regulating the safety and effectiveness of drugs, biologics, medical devices, and other products. In clinical trials, the FDA reviews data submitted by sponsors to decide whether a therapy is safe and effective enough to move forward in development or be approved for use.
Q3. What challenges do sponsors face when implementing real-time clinical trials?
A. Sponsors face several open questions as real-time models take shape: how blinded trials fit alongside continuous data sharing, what data quality and privacy standards apply to ongoing data exchange, and which trial types or technologies will qualify for FDA pilot programs. Beyond regulatory questions, sponsors also need the underlying infrastructure, interoperable data pipelines, automated signal detection, and standardized reporting to actually support real-time data flow from sites to regulators.
Q4. How do CROs benefit from AI-driven clinical trials?
A. AI-driven clinical trials give CROs earlier visibility into safety and efficacy signals, reducing the manual, multi-step process of collecting, analyzing, and submitting data. This can shorten trial timelines, reduce the operational burden of reporting, and position CROs to support sponsors who are pursuing FDA pilot programs or other real-time initiatives. CROs that already operate with automated, continuously updated data infrastructure are best positioned to participate as these models scale.
Q5. What is Continuous Clinical Development?
A. Continuous clinical development is the FDA’s longer-term vision in which the pause between clinical trial phases is reduced or eliminated. Today, each phase of drug development typically runs as a separate study with its own protocol, creating a hiatus before the next phase begins. Real-time data visibility is a foundational step toward continuous development, since it allows regulators to see key insights as a trial progresses rather than waiting for a phase to formally close.
